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A B S T R A C T
The aim of the study was to evaluate changes in electroencephalogram (EEG) recordings during the
course of acute lymphoblastic leukemia (ALL) in children. The study group consisted of 48 children with
ALL who underwent a total of 72 EEGs at various stages of the disease. The medical ﬁles were reviewed
for pertinent clinical data, and the EEGs were evaluated for changes in brain activity. Abnormal
background activity was noted in 52.2% of the EEGs done at 1–10 days of therapy, in 43.5% of those done
at 10–60 days, and only 4.3% of those done at later stages (p = 0.037). These ﬁndings, togetherwith earlier
reports, suggest that early-stage ALL, even before treatment, may be associated with excessive slow EEG
activity, which improves over time. The EEG changes, by themselves, are not an indication of central
nervous system leukemia or a predictor of later seizures or other central nervous system involvement.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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The central nervous system (CNS)may be involved in childhood
acute lymphoblastic leukemia (ALL), primarily in the disease
process but also as a treatment complication.1,2 Therefore,
electroencephalography is sometimes used as a measure of CNS
dysfunction in this setting.
Someof themedications used in the treatment of ALL are capable
of causing slow activity on the encephalogram (EEG)3 whereas
others are not.4 Lichter-Konecki et al.5 observed initial slowing of
background activityprior to therapy,with further slowing each time
treatment was administered. They attributed these ﬁndings to the
combined toxicity of vincristine and L-asparaginase. Sainio et al.6
reported that EEG abnormalities correlated with leukocytosis in
cerebrospinal ﬂuid (CSF) andwith the immunological cell typeof the
leukemia. In a study of serial EEGs in children with ALL in 1979,
Korinthenberg et al.7 noted that before treatment, ﬁndings were
normal in only 24% and abnormal in the remainder. In 57%, the EEG
abnormality could have been related to leukemic inﬁltrations. The
percentage of normal EEGs dropped to 11% during treatment and* Corresponding author at: Epilepsy Center, Schneider Children’s Medical Center
of Israel, Petach Tikva 49 100, Israel. Tel.: +972 3 925 3132; fax: +972 3 9253871.
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doi:10.1016/j.seizure.2010.11.016then rose to 65% after maintenance therapy. The authors concluded
thatanyEEGchanges in the courseofALLwerenotnecessarilydue to
the medication since they were present before treatment and
improvedwith therapy. In a later study, Korinthenberg8 suggested a
relationship between the EEG changes and the low CSF levels of
glutamine in the early stages of ALL, which presumably reﬂect a
decrease in neuronal excitatory activity. He concluded that the EEG
changes observed during the course of ALL were due to disease-
related factors and were not secondary to the drugs used in the
treatment protocol.
The aim of the present study was to further clarify the EEG
abnormalities, mainly slowing, during the course of ALL and their
possible relationship to therapy.
2. Patients and methods
The study group consisted of 48 of the 65 consecutive children
treated for ALL at Schneider Children’s Medical Center of Israel
between January 2001 and October 2003 who underwent
electroencephalographic studies before, during, and after therapy.
There were 34 boys and 14 girls aged 1.4–17 years. Forty-six
children were diagnosed and treated according to the ALL Berlin–
Frankfurt–Munster (BFM)-95 protocol, and 2, according to the
newer Intercontinental (IC)-BFM 2002 protocol.1 Risk stratiﬁcation
was as follows: standard risk, 5 children; medium risk, 39; high
risk, 4. The monoclonal cell type was pre-B in 35 children and T invier Ltd. All rights reserved.
Table 1
EEG ﬁndings for patients with acute lymphoblastic leukemia (48 patients, 72 EEGs).
No. of recordings %
Normal reading 45 62.5
Slowing
Generalized
Mild 15 20.8
Moderate 5 6.9
Severe 4 5.6
Focal intermittent 2 2.8
Generalized epileptiform discharge 1 1.4
[()TD$FIG]
Fig. 1. (A) Electroencephalogram of a girl with acute lymphoblastic leukemia aged
10 years and 11 months performed on day 6 of induction chemotherapy. Note
severe generalized slowing. (B) Electroencephalogram of the same girl on day 44 of
induction chemotherapy showing normal background.
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absence of neurological symptoms, normal ﬁndings on neurologi-
cal and funduscopic eye examinations, and normal CSF study. Past
medical history was unremarkable in all but 3 children who had a
history of febrile convulsions.
The48childrenunderwenta total of 72EEGs:38 recordingswere
performed as a baseline study, and the remainder for the following
indications: unusual sleepiness during treatment (4 children);
suspected seizures (3 children); confusional state or dizziness (one
child each); abnormal ﬁndings on magnetic resonance imaging
(MRI) (one child with an otherwise normal neurological examina-
tion), and follow-up (17 children). Twenty-ﬁve recordings were
performed at 1–0 days of therapy, 23 at 10–60 days, and 24 at later
stages (60 days to 3 years). All recordings were done with a 12-
channel machine using both referential and bipolar montages, and
all were analyzed by a qualiﬁed epileptologist (H.G.-S., S.K.). EEGs
with generalized slowing, focal slowing, or epileptiform discharges
were categorized as abnormal. Generalized slowing was further
characterized as follows:mild – alpha rhythm8HZ, reactive to eye
opening,with amild increase in theta frequency for age;moderate –
background consists of alpha rhythm, with a moderate increase in
theta and delta frequencies; severe – alpha rhythm absent, with
large amounts of theta and delta frequencies. For children younger
than 36 months, background activity was determined according to
EEG criteria appropriate for age.
The pertinent clinical and laboratory data were collected from
the ﬁles and related to the EEG ﬁndings.
BMDP statistical software was used for the statistical analysis.9
Discrete variables were analyzed with Pearson’s or chi-squared
test or Fisher’s exact test, as appropriate, and continuous variables
were analyzed with one-way analysis of variance (ANOVA) or non-
parametric Mann–Whitney U-test. A p-value of 0.05 was
considered signiﬁcant.
3. Results
The EEG ﬁndings are presented in Table 1. Abnormalities were
noted on 27 EEGs: generalized slowing in 24, focal slowing in 2, andTable 2
Clinical characteristics of patients with normal and abnormal EEG ﬁndings.
EEG
Abnormal (n=26)
Mean age (years) 5.94.0
Gender (%M:%F) 84.615.4
(22:4)
Mean white blood count/ml 65,575153.728
Mean hemoglobin (g/dl) 9.22.8
Mean platelet count/ml 126,808123,030
Duration of symptoms (days) 3128.3
Acute lymphoblastic leukemia risk stratiﬁcation:
Standard (%) 60
Medium (%) 54
High (%) 75
* Statistics: Fisher’s exact and nonparametric Mann–Whitney U-tests.epileptiform discharges in 1. Most (52.2%) of the abnormal slow
EEGs were recorded between 1 and 10 days of therapy; 43.5% were
recorded at 10 to 60 days, and 4.3% at 60 days or more (p = 0.0037).
Fifteen children underwent more than one electroencephalo-
graphic examination. Eight children in whom the initial EEG was
abnormal showed improvement (Fig. 1a and b). In one child, the
EEG ﬁndings worsened, and in the other 6, they were normal
initially and remained normal.
Comparison of the clinical characteristics between patients
with normal and abnormal ﬁndings on the ﬁrst EEG (Table 2)
yielded a statistically signiﬁcant association of abnormal back-p-value*
Normal (n=22)
8.43.8 0.036
54.545.5 0.029
(12:10)
74,150139.087 0.76
8.32.3 0.24
120,868194,744 0.24
33.750.35 0.84
40 0.54
46
25
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gender (p = 0.029). No signiﬁcant correlations were found for
duration of symptoms before diagnosis, initial white blood cell
count, hemoglobin value, or platelet count.
None of the children with abnormal EEG slowing had CNS
disease or later seizures.
Forty-one children also underwent MRI, 6 at onset of the
disease and 35 at later stages (after day 25). All 6 early scans were
normal whereas 29 of the 35 later scans (82%) showed
leukomalacia.
4. Discussion
The main ﬁnding of this study is the higher rate of abnormal
EEG slowing during the early stage of ALL (about 50%) than during
the later stages (4.3%), which was statistically signiﬁcant
(p = 0.0037).
The brain may be affected in patients with ALL as part of the
disease itself or as a complication of the chemotherapy. Our ﬁnding
that EEG slowing appears early in the course of the disease and
improves with therapy is in line with previous reports.3,4,10–14
Moreover, in a prospective study, Korinthenberg et al.8 found that
21 of 25 EEGs were abnormal before therapy and improved during
consolidation treatment.
Chemotherapy may have toxic effects on the CNS, mainly by
causing damage to the white matter.15 Korinthenberg and Igel13
suggested that in ALL, the improvement of EEG abnormalities over
time combined with late leukomalacia probably indicates that
nerve cells are not harmed by chemotherapy. This assumption was
supported by the MRI ﬁndings in the present study showing that
the late brain pathology consisted of leukomalacia/white matter
damage which became more prominent as chemotherapy contin-
ued, concomitant with improvement in EEG activity.
On the basis of the present and earlier studies, the character-
istics of EEG slowing in childhood ALL may be summarized as
follows:
(1) EEG slowing may be found at the early stages of the disease,
apparently even before the initiation of treatment.
(2) The slowing is alleviated during ALL treatment.
(3) EEG slowing, in itself, is not an indication of CNS leukemia.
(4) EEG slowing is not an indicator of the risk of later seizures or
other CNS involvement.
The cause of the EEG changes is unknown. Korinthenberg8
noted a correlation between background slowing on the EEG and
low CSF glutamine level at diagnosis of ALL. Glutamine is a
nonreactive form of glutamate, the main excitatory neurotrans-
mitter in the CNS. It also acts as a potential ‘‘fuel’’ to support
neuronal energy requirements.16 Changes in serum glutamine
level have been reported in different types of leukemia, and they
are probably attributable to metabolic changes induced by the
malignant cells.17 However, a relationship between a decrease in
neuroexcitation and EEG slowing is still speculative.The study was limited by its small sample size, retrospective
design, and lack of consistency among the patients in the day of
therapy on which the EEGs were performed.
In conclusion, the early stage of ALL may be associated with
subclinical asymptomatic encephalopathy manifested only by
excessive slow activity on the EEG. The mechanism that leads to
the EEG changes is still unknown, but it is presumed to involve
changes in the neuronal microenvironment, probably due to the
inﬂuence of certain humoral factors. Further research into this
question will also improve our knowledge of disorders other than
ALL. EEGs performed in childrenwith ALLwho do not have seizures
or CNS involvement can be misleading.
References
1. Pui CH, Evans WE. Acute lymphoblastic leukemia. New England Journal of
Medicine 1998;339:605–15.
2. Vainionpaa L. Clinical neurological ﬁnding of childrenwith acute lymphoblastic
leukemia at diagnosis and during treatment. European Journal of Pediatrics
1993;152:115–9.
3. Vainionpaa L, Saukkonen AL, Lanning M. Initial electroencephalographic ﬁnd-
ings in children with acute lymphoblastic leukaemia. Acta Paediatrica
1991;80:349–54.
4. Korinthenberg R, Schneider A, Niemeyer C. Central nervous system prophylaxis
with high-dose methotrexate does not give rise to signiﬁcant electroencepha-
lographic changes in children with acute lymphoblastic leukemia. Journal of
Child Neurology 2002;17:409–12.
5. Lichter-Konecki U, Benninger C, BrandeisWE,Matthis P, Scheffner D. Changes in
the EEG background activity of children with acute lymphoblastic leukemia
during cytotoxic therapy. Pediatric Hematology-Oncology 1987;4:77–85.
6. Sainio K, Rautonen J, Siimes MA. Value of EEG in childhood acute lymphoblastic
leukemia. Neuropediatrics 1989;20:82–3.
7. Korinthenberg R, Palm D, Rubig A, Schellong G. EEG changes during intensiﬁed
induction-therapy of acute lymphoblastic leukemia. Neuropadiatrie
1979;10:332–47.
8. Korinthenberg R. On the origin of EEG slowing and encephalopathy during
induction treatment of acute lymphoblastic leukemia. Medical and Pediatric
Oncology 2002;39:566–72.
9. DixonWJ, editor. BMPD statistical software. Los Angeles: University of California
Press; 1993.
10. Ueberall MA, Skirl G, Strassburg HM, Wenzel D, Hertzberg H, Langer T, et al.
Berger-Jones K, Korinthenberg R. Neurophysiological ﬁndings in long-term
survivors of acute lymphoblastic leukaemia in childhood treated with the
BFM protocol 81 SR-A/B. European Journal of Pediatrics 1997;156:727–33.
11. Ueberall MA, Wenzel D, Hertzberg H. Central nervous system late effects after
acute lymphoblastic leukemia therapy in childhood. Part II. Conventional EEG
recording in asymptomatic long-term survivors of childhood acute lympho-
blastic leukemia – an evaluation on the interferences between neurophysiolo-
gy, neurology, psychology and central nervous systemmorphology.Medical and
Pediatric Oncology 1997;29:121–31.
12. Lo-Nigro L, Di-Cataldo A, Schiliro G. Acute neurotoxicity in children with B-
lineage acute lymphoblastic leukemia (B-ALL) treated with intermediate risk
protocols. Medical and Pediatric Oncology 2000;35:449–55.
13. Korinthenberg R, Igel B. Prospective neurophysiological study in children
treated for acute lymphoblastic leukemia: serial EEG during treatment and
long-term follow-up with evoked potentials. European Journal of Pediatrics
1990;150:127–30.
14. Epstein CM. Sequential quantitative EEG analysis in acute lymphoblastic leu-
kemia. Clinical Electroencephalography 1985;16:208–12.
15. Siaderi G, Bollea A, Prencipe M, Giona F, Granati L, Pazzaglini A. A longitudinal
electroencephalography study in acute leukemia. Italian Journal of Neurologiocal
Sciences 1981;2:147–51.
16. Daikhin Y, Yudkoff M. Compartmentation of brain glutamate metabolism in
neurons and glia. Journal of Nutrition 2000;130(US Suppl.):1026S–31S.
17. Jaffe N. Metabolic and biochemical changes in leukemia. Modern Problems in
Paediatrics 1975;16:113–36.
